What strategic commissioning could mean for the uptake of innovative medicines.
Moving from Budget Management to Affordable Investment in Medicines
Live 1-hour webinar | Hosted by Soar Beyond
Tuesday 3rd February
12:00 - 13:00pm
Zoom
Why Attend?
As the NHS accelerates delivery of its long-term ambitions, the way medicines are commissioned is under increasing scrutiny. Traditional budget-led approaches are struggling to support the uptake of innovation at pace, particularly where medicines have the potential to improve outcomes, productivity and system sustainability.
This webinar explores how strategic commissioning offers a powerful reframe: moving from cost containment to affordable, outcome-focused investment in medicines.
Designed for a wide cross-section of the pharmaceutical industry, this session will challenge existing assumptions about access and invite fresh thinking on how industry can work with systems in new, more impactful ways.
What We'll Cover
-
What strategic commissioning means when applied to medicines and why it matters now
-
How a shift in mindset can enable greater uptake of innovative therapies
-
Where current access and innovation models fall short of NHS system needs
-
What a future-facing approach to medicines commissioning could look like
-
Why the NHS needs partners, not just suppliers, to deliver its 10-Year Plan objectives
Who Should Attend?
-
Market Access and Pricing leaders
-
Commercial and Strategy teams
-
Medical Affairs and Health Economics colleagues
-
Anyone involved in shaping how innovative medicines reach patients in the NHS
Why Soar Beyond?
Soar Beyond works at the intersection of policy, commissioning and frontline delivery, supporting systems to translate strategy into action. In this session, we will share a practical, system-level perspective on how pharma can engage differently and more effectively to support sustainable innovation adoption.